Literature DB >> 19428300

EBV in MS: guilty by association?

Jan D Lünemann1, Christian Münz.   

Abstract

Epstein-Barr Virus (EBV) is one of the most successful human viruses, infecting more than 90% of the adult population worldwide and persisting for the lifetime of the host. Individuals with a history of symptomatic primary EBV infection, called infectious mononucleosis, carry a moderately higher risk of developing multiple sclerosis (MS). In addition, EBV-specific immune responses, which crucially regulate the host-virus balance in healthy virus carriers, are altered in patients with MS. Although no data so far unequivocally support a direct etiologic role of the virus, recent studies allow for the development of testable hypotheses as to how EBV infection potentially promotes autoimmunity and central nervous system (CNS) tissue damage in MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428300     DOI: 10.1016/j.it.2009.03.007

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  20 in total

Review 1.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

2.  Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.

Authors:  Timothy C Cheung; Ken Coppieters; Hideki Sanjo; Lisa M Oborne; Paula S Norris; Amy Coddington; Steven W Granger; Dirk Elewaut; Carl F Ware
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

3.  [Multiple sclerosis: updates on pathogenesis and treatment: report from the 9th MS Symposium held by the German Multiple Sclerosis Society].

Authors:  R Hohlfeld; K V Toyka
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

4.  Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis.

Authors:  J W Lindsey; L M Hatfield; T Vu
Journal:  Eur J Neurol       Date:  2010-10       Impact factor: 6.089

Review 5.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

Review 6.  Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development.

Authors:  Yolanda S Kap; Jon D Laman; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-14       Impact factor: 4.147

7.  The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model.

Authors:  S Anwar Jagessar; Zahra Fagrouch; Nicole Heijmans; Jan Bauer; Jon D Laman; Luke Oh; Thi Migone; Ernst J Verschoor; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-19       Impact factor: 4.147

8.  Epstein-barr virus, the immune system, and associated diseases.

Authors:  Mei-Ru Chen
Journal:  Front Microbiol       Date:  2011-01-26       Impact factor: 5.640

9.  Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.

Authors:  Daniela F Angelini; Barbara Serafini; Eleonora Piras; Martina Severa; Eliana M Coccia; Barbara Rosicarelli; Serena Ruggieri; Claudio Gasperini; Fabio Buttari; Diego Centonze; Rosella Mechelli; Marco Salvetti; Giovanna Borsellino; Francesca Aloisi; Luca Battistini
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

10.  The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis.

Authors:  Bert A 't Hart; S Anwar Jagessar; Krista Haanstra; Ernst Verschoor; Jon D Laman; Yolanda S Kap
Journal:  Front Immunol       Date:  2013-06-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.